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Abstract: Organometallic ruthenium compounds that are effective anticancer and antimetastasis agents are cur-
rently under intensive investigation (see also the article by Peter Sadler in this issue). This article provides a per-
sonal account of the way in which we have exploited the different properties of the organoruthenium (and osmium
and rhodium) compounds to rival traditional DNA-binding platinum drugs, culminating in the discovery of a non-
classical molecule that is in an advanced stage of pre-clinical evaluation.
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has witnessed many promising develop-
ments in the field of medicinal chemistry,
with organometallic compounds displaying
anticancer and antimetastasis activity, and
finding applications as antibiotics, antiviral
and antiparasitic agents.
[7]
The unique properties of organometal-
lic compounds that makes them so promis-
ing in a range of medicinal applications are
not easily quantified, but it appears that the
increased stability that many exhibit over
conventional coordination compounds is
advantageous. The apparent advantage or-
ganometallic compounds may offer over
organic molecules is also important, with
increased drug uptake being one key factor,
and the potential for comparatively facile
design of multi-functional compounds (see
below). Thus, it appears that organometal-
lic compounds integrate the best features of
inorganic and organic compounds, although
much remains to be learnt in this respect.
Why Ruthenium−Arene Complexes?
Our initial reasons for wishing to
study the anti-proliferatine properties of
ruthenium(II)−arene complexes were based
on the notion that, to some extent, they
mirror square-planer platinum compounds
like cisplatin. In the simplest sense, two
chloride ligands which are able to undergo
hydrolysis are present, as in cisplatin, even
involving a similar substitution mechanism
by virtue of an ‘arene-slippage’ process.
Our initial studies on the anticancer prop-
erties of ruthenium(II)-arene compounds
[8]
began in the mid-1990s – undertaken while
I was at Imperial College, and at the same
time developing an interest in biphasic
synthesis and catalysis. In particular, we
were using/developing methods to transfer
organometallic catalysts between various
biphasic systems including water, organic
solvents and ionic liquids. This led us to
predict that the phosphorus donor ligand
pta that has been extensively studied by
Darensburg and others (including my own
group) in a catalytic context,
[9]
would pro-
vide hydrophilic properties that would be
nicely counterbalanced by the hydrophobic
arene region in a series of compounds based
on ruthenium (see below).
The other attractive feature of the
ruthenium−arene unit, that was subse-
quently developed after I moved to the
EPFL, is that it represents an excellent scaf-
fold on which to build functional organic
segments for targeted chemotherapy (Fig.
1). Ferrocene compounds have been used
in this way for quite some time. Notably,
the pioneering studies of Jaouen and his
group who have modified selective estro-
gen receptor modulator ligands with vari-
ous organometallic fragments including the
ferrocenyl group.
[10]
In addition, ruthenium is an attrac-
tive alternative to platinum: besides the
rich synthetic chemistry, ruthenium has a
range of oxidation states, Ru(II), Ru(III)
and Ru(IV), accessible under physiological
conditions,
[11]
and ruthenium compounds
tend to be generally less toxic than plati-
num compounds. In terms of mode of ac-
tion, the ability of ruthenium to mimic iron
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Introduction
The medicinal properties of inorganic (co-
ordination) compounds has been extensive-
ly studied due to their considerable success
in the clinic, notably cisplatin and other
platinum compounds,
[1]
with ruthenium
compounds recently commencing clinical
trials.
[2]
Organometallic compounds have
also had clinical applications for a long
time, a prominent example being the main-
group anti-syphilis drug Salvarsan
®
intro-
duced into the clinic in 1910,
[3]
although
its structure was only recently elucidated.
[4]
Transition metal-based metallocenes were
evaluated as anticancer compounds shortly
after the discovery of cisplatin,
[5]
in par-
ticular, titanocene dichloride has been
extensively studied and reached phase II
clinical trials, which were only recently
discontinued principally due to formulation
problems.
[6]
Nevertheless, the last decade
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in the binding to biological molecules, such
as albumin and transferrin, and the possi-
bility of proteomic targets is interesting,
[12]
since anticancer drugs are usually used in
combination therapy and excellent DNA
damaging drugs are already available, with
alternative targets identified in recent years
by molecular oncologists.
[13]
The low toxicity of indazolium trans-
[tetrachlorobis(1H-indazole)ruthenate(III)],
KP1019, is attributed, at least in part, to
transferrin-mediated drug transport,
[14]
with
KP1019 binding strongly to transferrin in
the iron-binding pockets.
[15]
Indeed, its
imidazolium analogue, which binds more
weakly to transferrin, is taken up less ef-
fectively by transferrin and is less cytotoxic
in vitro.
[16]
Another possible mechanism
in play is that the drug is activated by re-
duction, from Ru(III) to Ru(II), selectively
in hypoxic tumour tissue by endogenous
bioreductants such as gluthathione.
[17]
It appears that KP1019 induces apopto-
sis in colorectal cell lines predominantly
by the intrinsic mitochondria pathway
and that DNA could be a target, although
studies have shown that the DNA lesions
formed by KP1019 are different to those of
cisplatin.
[18]
Imidazolium trans-[tetrachloro
(DMSO)(imidazole)ruthenate(III)], NAMI-
A, binds within minutes to plasma pro-
teins,
[19]
inhibits lung metastases formation
and reduces metastases weight without af-
fecting the primary tumour.
[20]
Indeed, both
in vitro and in vivo data appear to exclude
DNA as the primary target, in line with the
observation that the binding of NAMI-A to
DNA is much weaker than platinum com-
plexes.
[21]
KP1019 and NAMI-A are both
progressing through clinical trials.
[2]
Activity
The prototype ruthenium−arene
compound emanating from our labora-
tory is [Ru(η
6
-cymene)Cl
2
(pta)], termed
RAPTA-C (Fig. 2).
[22]
RAPTA-C has been the subject of de-
tailed reactivity, computational, in vitro and
invivo studies. Inaqueoussolution, thechlo-
ride ligands may be hydrolysed, the extent
of which is dependant upon the concentra-
tion of the complex in solution, the amount
of chloride present and the pH.
[23]
Typically,
however, hydrolysis is suppressed in the
bloodplasmawherechlorideconcentration is
ca. 100 mM, but occurs once the compound
penetrates into the cell cytoplasm where
chloride concentrations are much lower, and
represents a possible activation pathway for
the compound. However, RAPTA-C deriva-
tives in which the chlorides have been re-
placed by chelating carboxylate ligands (Fig.
2) that resist hydrolysis display very similar
in vitro activity to RAPTA-C.
[24]
It is not
unreasonable to assume that arene slippage
(η
6
↔ η
4
) may therefore be important in any
activation pathway; such a mechanism has
been characterized in catalytic processes.
[25]
An arene slippage process in the context of
drug activation is still under investigation in
our laboratory. Additionally, the N-site on
the PTA ligand may be protonated, and in
RAPTA-C or the hydrolysed products the
pKa for this process is quite low, ca. 2–3,
and is unlikely to occur in a physiological en-
vironment. In general, reaction of RAPTA-
C with model oligonucleotides or proteins
results in adducts in which both chlorides
are lost (as expected following hydrolysis),
but also, in some cases loss of the arene
rings is observed.
[26]
Thus, the arene ap-
pears to be more labile than the PTA ligand
and this is substantiated by calculations. It
is difficult to imagine how an adduct which
has lost both chlorides and the arene could
bind to DNA, since five coordination sites
must be satisfied, which would suggest that
DNA is an unlikely target, and in vitro stud-
ies have shown that proteins and RNAs are
more probable targets.
[27]
Such data is in ac-
cordance with NAMI-A, and the similarity
between RAPTA-C and NAMI-A does not
end here. In vitro, RAPTA-C and NAMI-A
exhibit a very low activity, yet in vivo, both
compounds inhibit lung metastases in CBA
mice bearing the MCa mammary carcinoma,
reducing their weight and number, although
only mild effects on primary tumours are
observed.
[28]
They also exhibit low general
toxicity combined with excellent clearance
rates. In fact, RAPTA-C resulted in 40% of
animals being completely free of metasta-
sis after treatment and in general only drug
combination therapies showed better cure
rates.
[29]
Modulating Activity
Modificationof thebasicRAPTAframe-
work has been undertaken with a view to
understand its mode of action and to im-
prove its efficacy. In an attempt to increase
the cytotoxicity of the RAPTA compounds
functional groups with potential hydro-
gen bonding substituents were tethered to
the arene,
[30]
since this approach has been
shown to increase their affinity of metal-
based drugs to DNA/RNA.
[31]
However, this
modification actually resulted in a decrease
in toxicity towards cancer cells (traced to
decreased uptake) and an increase in toxic-
ity to non-tumourigenic cells. Experiments
Ru
Cl
Cl
P
N
N
N
PTA
biologically active group(s), targetting groups, etc.
modification alters
rate of hydrolysis -
also a site to
introduce labile
biologically active
groups
alkylation site - could be used to
attach functionalised groups,
modification of lypophilicity
replace wth osmium
Fig. 1. Generic RAPTA structure Ru(η
6
-arene)Cl
2
(pta) with potential sites for modification indicated.
Apart from ruthenium compounds we pioneered osmium analogues which also show promise.
Fig. 2. Solid-state structure of (left) RAPTA-C and (right) OxaloRAPTA-C
METALS IN MEDICINE 700
CHIMIA 2007, 61, No. 11
showed, however, that binding with a model
oligonucleotide increased. Using the same
functionalised arenes, but incorporating a
bulky hydrophobic ligand into the RAPTA
structure, resulted in increased drug uptake
and increased toxicity, but selectivity also
decreased relative to RAPTA-C (Fig. 3). In
fact, from a series of experiments it would
appear that as the capacity for DNA binding
increases, at the expense of selective pro-
tein interactions, the general toxicity of the
RAPTA drugs increases, which would po-
tentially lead tomoreside-effects inpatients.
Thus, modifying the RAPTA framework to
have increased interactions with proteins,
ideally specific interactions, should result
in a superior drug (see below).
Various other comparatively simple
modifications have been made, but none
resulted in a major improvement in activity.
For example, replacing the arene for other
isoelectronic ligands is possible without
causing major changes to activity/selectiv-
ity in vitro.
[32]
As mentioned above, replace-
ment of the chloride ligands for hydrolysis-
resistant chelates (or other simple groups)
did not have any significant effect on in
vitro activity although very hydrophobic
groups were recently found to significantly
increase uptake and cytotoxicity.
[33]
Use of
Me-PTA in place of PTA decreases selec-
tivity, presumably due to increased DNA
interactions due to the positive charge. Per-
haps most remarkably, changing the metal
itself,
[34]
e.g. for rhodium or osmium (Fig.
4) does not influence cytotoxicity to any
great extent on the cell lines tested.
Targeted Approaches
Of all the different RAPTA compounds
developed (see above) none proved to be
significantly more effective than RAPTA-
C. From the in vivo study, which was very
positive in terms of activity (including
also primery tumours in a recent study)
and pharmacokinetic parameters, the main
limitation of the RAPTA compounds is that
high doses are required for effective treat-
ment, although the lethal dose is very low
for a metal drug, i.e. comparable to para-
cetamol. While the various modifications
described in the previous section led to
increased cytotoxicity, the general toxicity
also increased in an unfavourable ratio or,
for example, addition of functional groups
such as benzocrown and imidazolium moi-
eties improved cytotoxicity it was not to a
significant degree to warrant further stud-
ies. Thus, we decided to adapt a method
we had developed for the rational design of
platinum drugs for a more targeted chemo-
therapeutic approach
[35]
to the RAPTA sys-
tem. As a strategy to enhance drug efficacy,
RAPTA complexes designed to inhibit Glu-
tathione-S-Transferases (GST), a cytosolic
detoxification enzyme associated with drug
resistance, were developed (Fig. 5),
[36]
since
inhibition of GST should allow the RAPTA
unit to operate at lower doses. RAPTA
complexes conjugated via the arene ring to
ethacrynic acid, a known inhibitor of GST
enzymes, were found to be effective GST
inhibitors with significantly increased cy-
totoxic activity, i.e. showing comparable or
superior cytotoxicity to cisplatin in various
cell lines known to contain elevated levels
of GST. Inhibition assays, mass spectrom-
etry binding experiments and X-ray struc-
tures of the ruthenium complexes bound
to the protein support our hypothesis that
these compounds act in a bifunctional man-
ner, i.e. inhibiting the enzyme and induc-
ing cytotoxicity following cleavage of the
inhibitor from the ruthenium. Higher cyto-
toxicities are observed for the ethacrynic
acid-RAPTA conjugate ethaRAPTA-N1
(Fig. 5) than cisplatin in certain cisplatin
resistance cell lines characterised by high
levels of GST.
Other enzyme targets have also been
investigated, for example Pgp, one of the
key proteins involved in multidrug resist-
ance.
[37]
In our initial studies we attached
modified known phenoxazine-type Pgp in-
hibitors to the ruthenium(II)−arene centre
via imidazole linkages (Fig. 6). However,
an anthracene structural analogue that was
found to be inactive on its own was far more
effective than the known inhibitors once
coordinated to the ruthenium(II) centre.
Studies showed that the complex induces
cell death via inhibition of DNA synthesis.
Moreover, since the complex is fluorescent,
its uptake in cells was studied, and relative
to the free anthracene-based ligand, uptake
of the complex is accelerated and accumu-
lation of the complex in the cell nucleus
was observed. While we had not anticipated
these additional benefits the accumulation
Fig. 3. Solid-state structure of (left) [Ru(η
6
-C
6
H
5
(CH
2
)
5
OH)Cl
2
(pta)] and (right) [Ru(η
6
-cymene)Cl(PPh
3
)
(pta)]BF
4
; examples of compounds which modulate the hydrophilicity/hydrophobicity of the RAPTA
structure and significantly modify the type of interactions with various biomolecular targets
Fig. 4. Solid-state structure of (left) [Rh(η
5
-C
5
Me
5
)Cl
2
(pta)] and (right) [Os(η
6
-cymene)Cl
2
(pta)];
examples of RAPTA analogues based on other platinum group metals that exhibit different ligand
exchange kinetics and redox properties
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of ruthenium in cell nuclei has already been
described for the phase II clinical trial drug
KP1019.
[38]
Other Compounds
With a view to rationally develop other
ruthenium-based antimetastatic agents, a
series of ruthenium(II)−arene imidazole
complexes have been prepared (Fig. 7),
combining the unique structural aspects of
NAMI-A and the ruthenium(II)−arene com-
plexes described herein.
[39]
The complexes
exhibit similar cytotoxicity with RAPTA
complexes in vitro (TS/A, HBL-100) and
several of the complexes exhibit selectiv-
ity towards cancer cells. We have also
started to explore the potential effects of
ruthenium−arene cluster compounds with
Georg Süss-Fink and Bruno Thierren at the
University of Neuchâtel and the latest re-
sults are very promising.
[40]
Development of Techniques
In parallel to our research on the devel-
opment of new drugs much of our efforts are
oriented towards rationalising drug delivery
and uptake mechanisms and determining
drug targets and binding modes. In particu-
lar, we use a combination of separation and
mass spectrometry techniques to achieve
these goals – both electrospray ionisation
and matrix assisted laser ablation.
[41]
Nota-
bly, we have developed a mass spectrometry
method that reveals preferential binding of
drugs to proteins from plasma
[14]
and whole
cell mixtures
[42]
and have shown that bind-
ing site data can be obtained.
[43]
Currently
we are expanding the method to human
cells and potentially biopsy samples using
2D gel electrophoresis methods. While we
have shown that specific compounds can in-
hibit certain enzymes (see above) it is clear
that in a cell multiple interactions may oc-
cur with different biomolecules and the elu-
cidation of these interactions should allow
us to design more selective compounds.
Concluding Remarks
The notion of using ruthenium(II)−arene
compounds as anticancer agents was first
described by Tocher and co-workers, who
coordinated theknownanticanceragent1-β-
metronidazole to the ruthenium(II)−benzene
fragment providing a compound with supe-
rior selective cytotoxicity than metronida-
zole itself.
[44]
Sadler has extensively studied
ruthenium(II)−arene complexes with ethyl-
enediamine and related ligands and their
results are summarised elsewhere,
[45]
while
Keppler’s group developed Ru(II)−arene
complexes with heterocyclic ligands.
[46]
A
Fig. 5. Solid-state structure of ethaRAPTA-N1; an example of a RAPTA
complex designed to overcome GST-mediated drug deactivation due to
the presence of the ethacrynic acid (GST inhibiting) group
Fig. 6. Solid-state structures of two ruthenium(II)-arene compounds: (left) [Ru(η
6
-p-cymene)
Cl
2
(phenoxbenzimide)] which contains a modified P-gp reversal agent as ligand and (right) [Ru(η
6
-
p-cymene)Cl
2
(anthraimid)] – a structural analogue in which the O
2
atom has been replaced by a CH
group
Fig. 7. Solid-state structure of (left) [Ru(η
6
-benzene)(mimid)
2
Cl]Cl and (right) [Ru(η
6
-benzene)
(mimid)
3
][BF
4
]
2
(mimid = N-methylimidazole); examples of hybrid RAPTA-NAMI antimetastatic drug
candidates
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series of ruthenium(II)−arene compounds
with disulfoxide ligands have been tested
in vitro for anticancer activity.
[47]
Our ap-
proach to combine aspects of both target-
ed and non-targeted chemotherapy into a
single molecule based on a ruthenium(II)-
arene frame has proven quite successful and
it should not be too long before we know
whether our lead compound, ethaRAPTA-
N1 – Fig. 5, will reach clinical trials. Due
to the very low toxicity of our compounds
applications beyond cancer may also be
possible.
[48]
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